NSEGeneral Updates18h ago · 15 Sept 2026, 07:53 pm
General Updates
Mankind Pharma Limited · MANKIND
✦ AI SummaryESG
Mankind Pharma Limited has informed the Exchange about its ESG Rating, which was assigned by Niche99 ESG Ratings as 68.21 under the 'Leader' category for FY 2025-26.
Analysis Scores
Earnings Impact1/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Mankind Pharma Limited has informed the Exchange about ESG Rating
Attachments (1)
📄pdf
Download →
MANKIND1_15092026195248_ESGRatings.pdf
View document text
September 15, 2026
BSE Limited National Stock Exchange of India Limited
P J Towers, Exchange Plaza, C-1, Block G,
Dalal Street, Bandra Kurla Complex,
Mumbai – 400 001 Bandra (E), Mumbai – 400 051
Scrip Code: 543904 Symbol: MANKIND
Dear Sir/ Madam,
Subject: Intimation of Environmental, Social and Governance (ESG) Rating
Ref.: Regulation 30 & 51 of Securities and Exchange Board of India (Listing
Obligations and Disclosure Requirements) Regulations, 2015 (“Listing
Regulations”)
Pursuant to Regulations 30 and 51 of the Listing Regulations, read with SEBI Master Circular
No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, we wish to inform
you that Niche99 ESG Ratings, a SEBI registered Category II ESG Rating Provider
(“Niche99”) has assigned the Company the rating of 68.21, under “Leader” category based on
the disclosures and data available in public domain for FY 2025-26.
Please note that the Company has not engaged Niche99 for ESG Ratings and that it has
independently prepared the report.
The above disclosure is also being made available on the Company’s website at
www.mankindpharma.com.
This is for your information and records.
Thanking You,
Yours Faithfully,
For Mankind Pharma Limited
Hitesh Kumar Jain
Company Secretary &
Compliance Officer